| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Tributylbenzylammonium bromide does not have a defined pharmacological target as it is a chemical reagent and surfactant. Quaternary ammonium compounds can interact with cell membranes and may exhibit antimicrobial activity through membrane disruption. The compound is used primarily as a phase-transfer catalyst and surfactant in organic synthesis rather than as a therapeutic agent. It may serve as a precursor for the synthesis of other bioactive quaternary ammonium compounds.
|
|---|---|
| ln Vitro |
Tributylbenzylammonium bromide is a biochemical reagent that can be utilized in research pertaining to life sciences as an organic substance or biological material.
No specific in vitro pharmacological activity data are available for tributylbenzylammonium bromide as it is a chemical reagent. In research settings, the compound is used as a phase-transfer catalyst and surfactant. Its activity is assessed in terms of catalytic efficiency, surface activity, and synthetic utility rather than biological activity. The compound facilitates reactions between reagents in different phases in organic synthesis. |
| ln Vivo |
No in vivo pharmacological activity data exist for tributylbenzylammonium bromide as it is not a therapeutic agent. The compound is used exclusively in chemical synthesis and is not administered to animals for pharmacological evaluation. Its applications are limited to organic chemistry laboratories.
|
| Enzyme Assay |
For non-cellular assays, tributylbenzylammonium bromide is characterized by standard analytical techniques including NMR, HPLC, and elemental analysis. The compound can be evaluated as a phase-transfer catalyst in organic reactions. Typical protocols involve dissolving the compound in aqueous or organic solvents and testing its ability to facilitate reactions between reagents in different phases. Purity is typically ≥98%. The compound is a solid at room temperature.
|
| Cell Assay |
Tributylbenzylammonium bromide is not used in cell-based assays as it is a chemical reagent rather than a biological test compound. The compound is intended for synthetic chemistry applications. If handled in a biological laboratory context, appropriate safety precautions should be taken due to the surfactant properties and potential membrane-disrupting effects. The compound should be stored in a cool, dry place protected from light and moisture.
|
| Animal Protocol |
Tributylbenzylammonium bromide is not used in animal studies as it is a chemical reagent. The compound is handled in chemistry laboratories with appropriate personal protective equipment. Storage: keep in a cool, dry place, protected from light and moisture. The compound should be stored in a tightly sealed container. Standard handling procedures for quaternary ammonium salts should be followed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable for tributylbenzylammonium bromide as it is a chemical reagent. The compound has a molecular weight of 356.39 and molecular formula C19H34BrN. It is a white to off-white crystalline powder. Storage: keep in a cool, dry place protected from light and moisture. Purity: typically ≥98%. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
Tributylbenzylammonium bromide is for research use only and not for human consumption. Standard laboratory safety practices should be followed when handling this chemical. Quaternary ammonium compounds can be irritating to skin, eyes, and mucous membranes. Appropriate personal protective equipment including gloves and safety glasses should be worn. Specific LD50 values and detailed toxicological profiles have not been extensively reported.
|
| Additional Infomation |
Tributylbenzylammonium bromide (CAS 25316-59-0) is also known as benzyltributylammonium bromide and N-benzyl-N,N-dibutylbutan-1-aminium bromide. It is used as a phase-transfer catalyst in organic synthesis and as a surfactant. No clinical trials or therapeutic approvals exist; the product is exclusively for research purposes.
|
| Molecular Formula |
C19H34BRN
|
|---|---|
| Molecular Weight |
356.38
|
| Exact Mass |
355.187
|
| CAS # |
25316-59-0
|
| Related CAS # |
54225-72-8 (Parent)
; 23616-79-7 (chloride)
; 25316-59-0 (bromide)
|
| PubChem CID |
2724282
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
169-171 °C
|
| LogP |
2.407
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
21
|
| Complexity |
196
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCC[N+](CCCC)(CC1=CC=CC=C1)CCCC.[Br-]
|
| InChi Key |
UDYGXWPMSJPFDG-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C19H34N.BrH/c1-4-7-15-20(16-8-5-2,17-9-6-3)18-19-13-11-10-12-14-19;/h10-14H,4-9,15-18H2,1-3H3;1H/q+1;/p-1
|
| Chemical Name |
benzyl(tributyl)azanium;bromide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8060 mL | 14.0300 mL | 28.0599 mL | |
| 5 mM | 0.5612 mL | 2.8060 mL | 5.6120 mL | |
| 10 mM | 0.2806 mL | 1.4030 mL | 2.8060 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
